2017.09.13. Preclinical POC data in a mouse Psoriasis model following Topical treatment with small molecule INV-17 ROR gamma inhibitor presented at the 2017 EADV Annual Meeting in Geneva, Switzerland

Written By Adam Parks

P1951: Topical administration of INV-17 small molecule ROR gamma inhibitor clinical candidate compound following disease induction in a mouse imiquimod-induced psoriasis disease model demonstrates therapeutic efficacy.

Read Here +

Adam Parks https://apollocreativeco.com
Previous

2018.02.16. Single-agent antitumor efficacy of a novel oral INV-25 Liver X receptor (LXR) agonist in a checkpoint-refractory mouse B16-F10 melanoma model presented at the 2018 AAD Meeting in San Diego
Next

2017.03.03. Psoriasis treatment efficacy of an Oral INV-17 ROR gamma inhibitor in a mouse Imiquimod Psoriasis model presented at the 2017 AAD Annual Meeting in Orlando, FL